Works about ERLOTINIB

Results: 1032
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring <bold>EGFR</bold> Mutations.

    Published in:
    Oncology, 2018, v. 95, n. 2, p. 109, doi. 10.1159/000488594
    By:
    • Nishinarita, Noriko;
    • Igawa, Satoshi;
    • Kasajima, Masashi;
    • Kusuhara, Seiichiro;
    • Harada, Shinya;
    • Okuma, Yuriko;
    • Sugita, Keisuke;
    • Ozawa, Takahiro;
    • Fukui, Tomoya;
    • Mitsufuji, Hisashi;
    • Yokoba, Masanori;
    • Katagiri, Masato;
    • Kubota, Masaru;
    • Sasaki, Jiichiro;
    • Naoki, Katsuhiko
    Publication type:
    Article
    10

    A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Oncology, 2018, v. 94, n. 6, p. 329, doi. 10.1159/000485384
    By:
    • Thomas, Melanie B.;
    • Garrett-Mayer, Elizabeth;
    • Anis, Munazza;
    • Anderton, Kate;
    • Bentz, Tricia;
    • Edwards, Andie;
    • Brisendine, Alan;
    • Weiss, Geoffrey;
    • Siegel, Abby B.;
    • Bendell, Johanna;
    • Baron, Ari;
    • Duddalwar, Vinay;
    • El-Khoueiry, Anthony
    Publication type:
    Article
    11
    12
    13
    14
    15

    FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).

    Published in:
    Journal of Clinical Medicine, 2022, v. 11, n. 9, p. 2475, doi. 10.3390/jcm11092475
    By:
    • Raphael, Ari;
    • Dudnik, Elizabeth;
    • Hershkovitz, Dov;
    • Jain, Suyog;
    • Olsen, Steve;
    • Soussan-Gutman, Lior;
    • Ben-Shitrit, Taly;
    • Dvir, Addie;
    • Nechushtan, Hovav;
    • Peled, Nir;
    • Onn, Amir;
    • Agbarya, Abed
    Publication type:
    Article
    16
    17
    18

    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

    Published in:
    Oncologist, 2024, v. 29, n. 7, p. 596, doi. 10.1093/oncolo/oyae043
    By:
    • Pasello, Giulia;
    • Lorenzi, Martina;
    • Scattolin, Daniela;
    • Conte, Alessandro Del;
    • Cecere, Fabiana;
    • Pavan, Alberto;
    • Macerelli, Marianna;
    • Polo, Valentina;
    • Pilotto, Sara;
    • Santarpia, Mariacarmela;
    • Cumerlato, Enrico;
    • Ros, Valentina Da;
    • Targato, Giada;
    • Bortolami, Alberto;
    • Bonanno, Laura;
    • Ferro, Alessandra;
    • Maso, Alessandro Dal;
    • Frega, Stefano;
    • Guarneri, Valentina
    Publication type:
    Article
    19

    Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.

    Published in:
    Oncologist, 2022, v. 27, n. 1, p. 7, doi. 10.1093/oncolo/oyab002
    By:
    • Morabito, Alessandro;
    • Manzo, Anna;
    • Montanino, Agnese;
    • Rachiglio, Anna Maria;
    • Sforza, Vincenzo;
    • Pasquale, Raffaella;
    • Costanzo, Raffaele;
    • Maiello, Monica R;
    • Sandomenico, Claudia;
    • Gallo, Marianna;
    • Palumbo, Giuliano;
    • Luca, Antonella De;
    • La Rocca, Antonello;
    • Martucci, Nicola;
    • Cecio, Rossella De;
    • Picone, Carmine;
    • Lastoria, Secondo;
    • Normanno, Nicola
    Publication type:
    Article
    20
    21
    22
    23
    24

    Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer.

    Published in:
    Oncologist, 2019, v. 24, n. 8, p. 1095, doi. 10.1634/theoncologist.2018-0695
    By:
    • Sequist, Lecia V.;
    • Gray, Jhanelle Elaine;
    • Harb, Wael A.;
    • Lopez‐Chavez, Ariel;
    • Doebele, Robert C.;
    • Modiano, Manuel R.;
    • Jackman, David Michael;
    • Baggstrom, Maria Quintos;
    • Atmaca, Akin;
    • Felip, Enriqueta;
    • Provencio, Mariano;
    • Cobo, Manuel;
    • Adiwijaya, Bambang;
    • Kuesters, Geoffrey;
    • Kamoun, Walid S.;
    • Andreas, Karen;
    • Pipas, J. Marc;
    • Santillana, Sergio;
    • Cho, Byoung Chul;
    • Park, Keunchil
    Publication type:
    Article
    25

    From Diagnostic‐Therapeutic Pathways to Real‐World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR‐Positive Non‐Small Cell Lung Cancer (MOST Study).

    Published in:
    Oncologist, 2019, v. 24, n. 6, p. e318, doi. 10.1634/theoncologist.2018-0712
    By:
    • Pasello, Giulia;
    • Vicario, Giovanni;
    • Zustovich, Fable;
    • Oniga, Francesco;
    • Gori, Stefania;
    • Rosetti, Francesco;
    • Bonetti, Andrea;
    • Favaretto, Adolfo;
    • Toso, Silvia;
    • Redelotti, Roberta;
    • Santo, Antonio;
    • Bernardi, Daniele;
    • Giovanis, Petros;
    • Oliani, Cristina;
    • Calvetti, Lorenzo;
    • Gatti, Carlo;
    • Palazzolo, Giovanni;
    • Baretta, Zora;
    • Bortolami, Alberto;
    • Bonanno, Laura
    Publication type:
    Article
    26

    Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer.

    Published in:
    Oncologist, 2019, v. 24, n. 6, p. e251, doi. 10.1634/theoncologist.2018-0089
    By:
    • Buttigliero, Consuelo;
    • Shepherd, Frances A.;
    • Barlesi, Fabrice;
    • Schwartz, Brian;
    • Orlov, Sergey;
    • Favaretto, Adolfo G.;
    • Santoro, Armando;
    • Hirsh, Vera;
    • Ramlau, Rodryg;
    • Blackler, Adele R.;
    • Roder, Joanna;
    • Spigel, David;
    • Novello, Silvia;
    • Akerley, Wallace;
    • Scagliotti, Giorgio V.
    Publication type:
    Article
    27

    A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).

    Published in:
    Oncologist, 2019, v. 24, n. 5, p. 589, doi. 10.1634/theoncologist.2018-0878
    By:
    • Halfdanarson, Thorvardur R.;
    • Foster, Nathan R.;
    • Kim, George P.;
    • Meyers, Jeffrey P.;
    • Smyrk, Thomas C.;
    • McCullough, Ann E.;
    • Ames, Matthew M.;
    • Jaffe, Jeffrry P.;
    • Alberts, Steven R.
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

    Published in:
    Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00132
    By:
    • Reckamp, Karen L.;
    • Frankel, Paul H.;
    • Ruel, Nora;
    • Mack, Philip C.;
    • Gitlitz, Barbara J.;
    • Li, Tianhong;
    • Koczywas, Marianna;
    • Gadgeel, Shirish M.;
    • Cristea, Mihaela C.;
    • Belani, Chandra P.;
    • Newman, Edward M.;
    • Gandara, David R.;
    • Lara, Primo N.
    Publication type:
    Article
    49
    50